Abstract 1419
Background
PBMCs respond to adverse physiological conditions to maximize survival and to alleviate the threat. Hsp70 is produced to maintain protein function and activates an immune response. Autophagy is induced to provide sufficient nutrients in response to accelerated gene activation. We tested the hypothesis that PBMCS respond to the presence of a malignant breast mass by increasing production of hp70 and manifesting a higher level of autophagy.
Methods
In this pilot study seventy women had their breast mass evaluated by mammogram and/or breast ultrasound. A core biopsy and surgery was performed as indicated. PBMCs were isolated from peripheral blood, lysed and intracellular levels of hsp70 and p62 (a measure of autophagy) were quantitated by ELISA. Extracellular hsp70 in plasma was also measured. Differences in lab measurements between women with a diagnosis of a benign or malignant breast mass were determined. All assays were performed by personnel blinded to the clinical data.
Results
A breast malignancy was diagnosed in 42 women while 28 had a benign lesion. Plasma hsp70 levels were higher in women with a malignant lesion (p = 0.03). PBMCs from 46 women were available for analysis. Mean hsp70 levels were higher in PBMCs from 38 women with a malignant lesion than in 8 women with a benign breast mass (p = 0.04). The PBMC p62 levels were higher in women with a benign breast lesion than in those with a malignant breast mass (p < 0.0001). Since p62 is inversely related to the level of autophagy this indicates that autophagy is higher in PBMCs from women with a malignant breast lesion. There was no difference in the concentration of hsp70 or p62 between women with different histological types or stage of breast cancer.
Conclusions
Detection of elevated levels of hsp70 and autophagy in PBMCs, and higher plasma hsp70 levels, may differentiate between women with a malignant or benign breast lesion. Further studies on a larger sample are needed to confirm if the extent of autophagy and hsp70 induction in PBMCs may be of value in the preoperative triage of women with a breast mass.
Clinical trial identification
Legal entity responsible for the study
Weill Cornell Medicine.
Funding
Weill Cornell Medicine.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract